The purpose of this EU survey is to gain understanding on the needs of companies/organisations in the EU working on the development of new and repurposed medicines for COVID-19 therapeutics, i.e. medicines specifically developed for an indication…
SPARK Europe will be regularly featured on the podcast series BioInnovation Spotlight “Shining a Light on The Next Big Thing“, a podcast series produced for and with LifeScience ORG.
Dr. Felix Lorenz, SPARKee and founder of the Berlin-based…
Myelo Therapeutics GmbH, a clinical-stage pharmaceutical company focused on developing medical countermeasures (MCM) and therapies for cancer supportive care, announced today that the U.S. National Institute of Allergy and Infectious Diseases…
Join one of our webinars to gain insights about this year’s partnership opportunities for digital health innovators with Bayer G4A!
We will reflect on the implications of the Covid-19 pandemic for digital health…
Berlin, May 12, 2021 - Today the 15th Speed Lecture Award took place as part of BIONNALE, again as a live-stream and with over 750 registrations.
A collaboration between Berlin, London, New York and Paris to leverage our collective innovation and speed our recovery from Covid-19
Investment will strengthen technology and expand company’s reach
The Russian Direct Investment Fund (RDIF, Russia’s sovereign wealth fund), Egypt’s Minapharm, the regional leader in recombinant DNA technology, and its Berlin-based subsidiary ProBioGen AG announce the agreement to produce over 40 million doses per…
What is the Speed Lecture Award?
Young scientists present in three minutes their new projects and ideas in life sciences and healthcare industries in front of the BIONNALE audience of more than 600 experts from academia, science and business.
ProBioGen AG is delighted to announce the signing of a service agreement for Nobelpharma’s highly relevant vaccine project.
Earlier work confirmed already the versatility and benefit of ProBioGen’s vaccine development platform, consisting of the…
